CMND
Clearmind Medicine·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Stock Price Surged Significantly
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CMND
Clearmind Medicine Inc.
A pharmaceutical company developing a new psychedelic drug
Life Science Tools and Services
07/18/2017
11/15/2022
NASDAQ Stock Exchange
3
10-31
Common stock
101–1220 West 6th Avenue, Vancouver, British Columbia V6H1A5
--
Clearmind Medicine Inc., was incorporated in British Columbia on July 18, 2017. They are a preclinical pharmaceutical company approaching a phase 1 clinical trial, developing new psychedelic drugs to address a widespread but underserved health problem. Their goal is to develop and offer a new type of treatment for AUD, including binge eating disorder, where there is a large unmet need and lack of innovation.
Company Financials
EPS
CMND has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected 0, missing expectations. The chart below visualizes how CMND has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
